FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study.

被引：0
|
作者：
Li, Qiao
Cheng, Ying
Tong, Zhongsheng
Liu, Yunjiang
Wang, Xian
Yan, Min
Chang, Jianhua
Wang, Shusen
Du, Caiwen
Li, Liang
Wu, Chunjiao
Wang, Mingxia
Wang, Zhuo
Wu, Zhuli
Jin, Yongli
Zhang, Yongjiao
Hui, Ai-Min
Wang, Xingli
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Dept Med Oncol, Canc Hosp, Beijing, Peoples R China
[2] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Tianjin, Peoples R China
[4] Hebei Med Univ, Dept Breast Ctr, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[6] Zhengzhou Univ, Dept Breast Dis, Henan Breast Canc Ctr, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[7] Henan Canc Hosp, Zhengzhou, Peoples R China
[8] Chinese Acad Med Sci, Shenzhen Ctr, Dept Med Oncol, Canc Hosp, Shenzhen, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[10] Meizhou Peoples Hosp, Dept Med Oncol, Meizhou, Guangdong, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Phase ward 1, Changchun, Jilin, Peoples R China
[12] Hebei Med Univ, Dept Phase 1, Clin Trial Unit, Hosp 4, Shijiahuang, Hebei, Peoples R China
[13] Beijing Fosun Pharmaceut Res & Dev Co Ltd, Shanghai, Peoples R China
[14] Fosun Pharma USA Inc, Lexington, MA USA
[15] Shanghai Fosun Pharmaceut Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3044
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS
    Jackisch, C.
    Dank, M.
    Frasci, G.
    Park, K. H.
    Lopez, R. I.
    Johnston, M.
    Heinzmann, D.
    Weber, H.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 103
  • [22] Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)
    Woodward, N.
    De Boer, R. H.
    Redfern, A.
    White, M.
    Young, J.
    Truman, M.
    Beith, J.
    CANCER RESEARCH, 2016, 76
  • [23] Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study
    Ciruelos, Eva
    Pascual, Tomas
    Oliveira, Mafalda
    Escriva-de-Romani, Santiago
    Pernas, Sonia
    Pare, Laia
    Adamo, Barbara
    Martinez, Eduardo
    Cortes, Javier
    Perello, Antonia
    Galan, Maria
    Mele, Mireia
    Tolosa, Pablo
    Gonzalez-Farre, Blanca
    Galvan, Patricia
    Canes, Jordi
    Nuciforo, Paolo
    Gonzalez, Xavier
    Villagrasa, Patricia
    Prat, Aleix
    CANCER RESEARCH, 2022, 82 (04)
  • [24] Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.
    Chen, Xiaosong
    Huang, Jiahui
    Tong, Yiwei
    Ren, Weili
    Yu, Jing
    Gao, Weiqi
    Zhu, Siji
    Hong, Jin
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] MetaPHER: A phase IIlb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer
    Kummel, S.
    Crepelle-Flechais, A.
    Schlegel, M.
    Hillenbach, C.
    Swat, A.
    Franz, M.
    Girase, P.
    Schneider, A.
    Heinzmann, D.
    Shing, M.
    CANCER RESEARCH, 2016, 76
  • [26] PREDICTION OF PFS BASED ON TUMOR GROWTH INHIBITION METRICS IN HER2 POSITIVE BREAST CANCER PATIENTS FOLLOWING HER2 ADC FS-1502 TREATMENT
    Diao, L.
    Zhou, C.
    Sun, Y.
    Xiang, X.
    Li, C.
    Hua, H.
    Wang, X.
    Zheng, Y.
    Wu, Z.
    Qiu, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S98 - S99
  • [27] Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
    Pivot, Xavier
    Gligorov, Joseph
    Mueller, Volkmar
    Barrett-Lee, Peter
    Verma, Sunil
    Knoop, Ann
    Curigliano, Giuseppe
    Semiglazov, Vladimir
    Lopez-Vivanco, Guillermo
    Jenkins, Valerie
    Scotto, Nana
    Osborne, Stuart
    Fallowfield, Lesley
    LANCET ONCOLOGY, 2013, 14 (10): : 962 - 970
  • [28] 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
    Goldhirsch, Aron
    Gelber, Richard D.
    Piccart-Gebhart, Martine J.
    de Azambuja, Evandro
    Procter, Marion
    Suter, Thomas M.
    Jackisch, Christian
    Cameron, David
    Weber, Harald A.
    Heinzmann, Dominik
    Dal Lago, Lissandra
    McFadden, Eleanor
    Dowsett, Mitch
    Untch, Michael
    Gianni, Luca
    Bell, Richard
    Koehne, Claus-Henning
    Vindevoghel, Anita
    Andersson, Michael
    Brunt, A. Murray
    Otero-Reyes, Douglas
    Song, Santai
    Smith, Ian
    Leyland-Jones, Brian
    Baselga, Jose
    LANCET, 2013, 382 (9897): : 1021 - 1028
  • [29] Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label randomized, multicenter, phase IIIB ESCAPE trial
    Kaidarova, Dilyara
    Zhavrid, Edvard
    Shatkovskaya, Oxana
    Prokharau, Aliaksandr
    Akhmed, Nina
    Sembayev, Dauren
    Rutzhanova, Zhanna
    Ivankov, Alexandr
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
  • [30] An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
    Cicin, Irfan
    Oukkal, Mohammed
    Mahfouf, Hassen
    Mezlini, Amel
    Larbaoui, Blaha
    Ben Ahmed, Slim
    Errihani, Hassan
    Alsaleh, Khalid
    Belbaraka, Rhizlane
    Yumuk, Perran Fulden
    Goktas, Burce
    Ozguroglu, Mustafa
    EUROPEAN JOURNAL OF BREAST HEALTH, 2022, 18 (01) : 63 - 73
12345